Ex-vivo CRISPR edits cells outside the body before reinfusion. In-vivo editing sends the editing machinery directly into a patient, potentially making treatment simpler but far harder to control.
Personalized neoantigen vaccines turn mutations from an individual patient’s tumor into a custom immunotherapy, requiring sequencing, computational prediction and manufacturing to occur within the treatment window.
Targeted protein degraders do not simply occupy a disease protein and block its activity. They recruit the cell’s disposal machinery to remove it, potentially opening targets conventional drugs cannot reach.
FDA-cleared OTC glucose sensors have opened continuous monitoring to people who do not use insulin, but evidence for weight loss and broad metabolic improvement in people without diabetes remains limited.
Circulating tumor DNA can detect molecular traces of residual cancer after apparently curative treatment, but proving that acting on an earlier signal improves survival is the harder challenge.
Oral semaglutide demonstrated that a peptide can become a successful tablet, but extremely low and variable gastrointestinal absorption still makes most peptides poor candidates for oral delivery.
Radiotheranostics pairs molecular imaging with targeted radioactive drugs, allowing clinicians to confirm whether a tumor carries the therapeutic target before delivering radiation systemically.
Antibody-drug conjugates combine targeting antibodies with powerful cytotoxic payloads, but clinical performance increasingly depends on linker chemistry, drug-to-antibody ratio, payload properties and how the medicine behaves inside heterogeneous tumors.
FDA cleared Cubresa BrainPET as a Class II PET-MR imaging system, allowing the removable brain-dedicated PET insert to be used with compatible Siemens infrastructure.
FDA written feedback supports a potential pivotal expansion of REO 033 using response rate and duration as an accelerated-approval strategy, but Oncolytics must first generate supportive randomized Part A data.